Carmot Therapeutics
(Note: Carmot Therapeutics withdrew its IPO plans in an SEC letter dated Dec. 11, 2023. Roche announced earlier in December that it would acquire the Berkeley, California-based biotech for about $2.7 billion.) We are a Phase 2 clinical biotechnology company developing drugs to treat obesity and diabetes. (Incorporated in Delaware) We are a clinical-stage biotechnology […]
November 18, 2023 Read More